The effect of peri-operative magnesium sulfate infusion on inflammatory factors in patients with lung cancer

Cancer institute0 个研究点目标入组 44 人开始时间: 待定最近更新: 2022年5月2日

试验速览

暂无简介。

•Patients with stage I (cT1N0 and cT2N0), stage II (cT1N1, cT2N1 and cT3N0) lung cancer
•Age 18 to 65 years old
•Candidate for lobectomy or pneumoectomy surgery
•Informed consent

•History of severe heart disease, severe systemic and functional lung disease (asthma, COPD)
•Electrolyte disturbance
•BMI below 16
•concurrent history of other cancers
•Albumin level less than 5.2
•stage IIIA (cT3N1 and cT1–3N2) lung cancer and above
•Small cell carcinoma
•HIV positive or any immunodeficiency
•Patients undergoing clinical trial studies at the same time as this study
•Dissatisfaction with participating in the study
•Incomplete tumor resection (potential effect on cytokine levels)
•Long incision on chest wall, diaphragm or mediastinum
•Prescribing corticosteroids
•Pulmonary fibrosis (affected IL-8)
•History of chemotherapy and radiotherapy during the past month
•Patients with severe chronic renal failure (creatinine clearance less than 30 ml / min)
•Patients with acute renal failure and anuria
•Patients treated with drugs that produce hypermagnesemia (such as spironolactone, eplerenone)

发起方

Cancer institute